bioRxivSystems Biology
Simulating serial-target antibacterial drug synergies using flux balance analysis
Andrew S Krueger, Christian Munck, Gautam Dantas, George M Church, James Galagan, Joseph Lehar, Morten OA Sommer
Abstract
Flux balance analysis (FBA) is an increasingly useful approach for modeling the behavior of metabolic systems. However, standard FBA modeling of genetic knockouts can not predict drug combination synergies observed between serial metabolic targets, even though such synergies give rise to some of the most widely used antibiotic treatments. Here we extend FBA modeling to simulate responses to chemical inhibitors at varying concentrations, by diverting enzymatic flux to a waste reaction. This flux diversion yields very similar qualitative predictions to prior methods for single target activity. However, we find very different predictions for combinations, where flux diversion, which mimics the kinetics of competitive metabolic inhibitors, can explain serial target synergies between metabolic enzyme inhibitors that we confirmed in Escherichia coli cultures. FBA flux diversion opens the possibility for more accurate genome-scale predictions of drug synergies, which can be used to suggest treatments for infections and other diseases.
- organism: E. coli
- research focus: drug response / drug discovery
- approach: statistical model
- approach: simulation
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A flux-based machine learning model to simulate the impact of pathogen metabolic heterogeneity on drug interactions
Carolina H. Chung, Sriram Chandrasekaran·PNAS NexusPeer-reviewed·Jul 1, 2022
- Topological Complementarity Predicts Synergistic Drug Pairs in Branched Metabolic Networks.
Deeptanshu Pandey, Purbita Sikdar, … Sourav Chowdhury·bioRxiv·Oct 27, 2026
- A Mechanistic Approach to Optimize Combination Antibiotic Therapy
Fabrizio Clarelli, Pierre Ankomah, … Pia Abel zur Wiesch·BiosystemsPeer-reviewed·Dec 24, 2024
- Mutations in the riboflavin biosynthesis pathway confer resistance to furazolidone and abolish the synergistic interaction between furazolidone and vancomycin in Escherichia coli.
Hannah Wykes, Vuong Van Hung Le, Jasna Rakonjac·Microbial GenomicsPeer-reviewed·Feb 11, 2025
- Understanding the host-microbe interactions using metabolic modeling
S. El Aidy, J. Jansma·MicrobiomePeer-reviewed·Jan 20, 2021
- In vitro synergy between Sodium Deoxycholate and Furazolidone against Enterobacteria via Inhibition of Multidrug Efflux Pumps
V. V. H. Le, C. Olivera, … J. Rakonjac·bioRxiv·Jan 11, 2019